Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a biotechnology company focused on developing treatments for cystic fibrosis and other serious diseases, with a primary political signal being $6.68M in annual payments to doctors and healthcare professionals.
BusinessWhat VRTX does
Vertex Pharmaceuticals researches, develops, and commercializes therapies for cystic fibrosis, sickle cell disease, beta thalassemia, and other serious diseases. Its revenue is primarily generated from sales of its CFTR modulator drugs. The company operates in the highly regulated pharmaceutical sector, with no direct federal contract revenue or reported lobbying spend.
12 months past · 3 months futureVRTX activity timeline
Executive Branch ConflictsVRTX held by Trump-administration officials
Lifetime Government AwardsVRTX federal contracts
VRTX doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Smart Money · 13F HoldingsHedge funds holding VRTX
Politicians Trading VRTXMembers of Congress with recent VRTX positions
Congressional TradesWho in Congress is trading VRTX
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
Stock awards & option exercises
Bills Affecting VRTXLive legislation impacting this stock
Political ProfileWhere VRTX sits in Washington
[object Object]
STRUCTURAL: High regulatory density from 8 identified pharma bills. No lobbying spend, federal contracts, or partisan donation patterns. EVIDENTIARY: Significant annual doctor payments ($6.68M in 2024 per `get_political_influence.doctor_payments`). CEO insider purchase of ~$2.23M in August 2025. Executive branch exposure via Trump holdings (3 positions, value $1K-$50K per `get_executive_branch_exposure`). Congressional trading is limited and net neutral (Rep. T000490 bought and sold similar amounts). Net: High regulatory risk offset by strong commercial relationships and insider buying; executive branch holdings are a minor structural note.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Broad legislative pressure on pharmaceutical pricing and revenueU.S. Congress"Eight recent bills in `Recent bill_impacts` with impact_ratios up to 0.0002 and estimated revenue impacts up to $22.5M."
Regulatory opportunities
- No specific regulatory opportunities flagged.
Live signals + predictions for VRTX — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades VRTX
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord